NanoViricides' flu drug candidates demonstrate oral effectiveness

US drug developer NanoViricides (OTCBB: NNVC) says that anti-influenza drug candidates under its FluCide program, when given orally, were nearly as effective as when administered as IV injections. Two different anti-influenza drug candidates were tested in oral versus IV comparison, and both of them showed similar results that indicated strong oral effectiveness.

Beats Tamiflu in animal model

According to the company, the results clearly demonstrated that oral administration of both of these FluCide drug candidates resulted in substantially superior animal protection compared to oseltamivir (Tamiflu, from Swiss drug major Roche), a standard of care for influenza at present. The studies involved the same highly lethal animal model the company has continued to use for its influenza drug development program.